TransCode Therapeutics (NASDAQ:RNAZ) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ) in a report released on Friday morning, Benzinga reports. The brokerage currently has a $3.00 price target on the stock.

TransCode Therapeutics Price Performance

RNAZ opened at $0.26 on Friday. TransCode Therapeutics has a 1 year low of $0.22 and a 1 year high of $128.00. The company’s 50 day simple moving average is $0.45 and its 200 day simple moving average is $0.74.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.16). As a group, sell-side analysts anticipate that TransCode Therapeutics will post -2.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TransCode Therapeutics

An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC acquired a new stake in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned approximately 0.84% of TransCode Therapeutics at the end of the most recent reporting period.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.